Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junichi Kitagawa

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Hematological Oncology|June 25, 2016
Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specifiedYuhei Shibata, Takeshi Hara, Takuro Matsumoto, et al.
Hematological Oncology|October 10, 2015
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicinYuhei Shibata, Takeshi Hara, Senji Kasahara, et al.
Hematological Oncology|December 26, 2025
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell LymphomaYoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, et al.
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
Hematological Oncology|June 9, 2018
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trialTakeshi Hara, Takeshi Yoshikawa, Hideko Goto, et al.
Leukemia|April 21, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AMLYoshikazu Ikoma, Nobuhiko Nakamura, Yuto Kaneda, et al.
Leukemia|May 17, 2019
Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profilingYosaku Watatani, Yasuharu Sato, Hiroaki Miyoshi, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Hematological Oncology|June 25, 2016
Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specifiedYuhei Shibata, Takeshi Hara, Takuro Matsumoto, et al.
Hematological Oncology|October 10, 2015
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicinYuhei Shibata, Takeshi Hara, Senji Kasahara, et al.
Hematological Oncology|December 26, 2025
Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High-Dose Cytarabine-Based Chemotherapy as Second-Line Treatments for Relapsed or Refractory Diffuse Large B-Cell LymphomaYoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, et al.
International Journal of Hematology|June 14, 2022
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myelomaSatsuki Murakami, Masaki Ri, Masato Ito, et al.
Hematological Oncology|June 9, 2018
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trialTakeshi Hara, Takeshi Yoshikawa, Hideko Goto, et al.
Leukemia|April 21, 2025
Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AMLYoshikazu Ikoma, Nobuhiko Nakamura, Yuto Kaneda, et al.
Leukemia|May 17, 2019
Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profilingYosaku Watatani, Yasuharu Sato, Hiroaki Miyoshi, et al.
Pageof 11